erlotinib tablets is a kinase inhibitor indicated for: \u2022 Maintenance treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose disease has not progressed after four cycles of platinum-based first-line chemotherapy. \u2022 Treatment of locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. \u2022 First-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer, in combination with gemcitabine.<\/p>\n
If erlotinib tablets are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
Erlotinib is used to treat certain types of non-small cell lung cancer that has spread to nearby tissues or to other parts of the body in patients who have already been treated with at least one other chemotherapy medication and have not gotten better.<\/p>\n
Approval Date: 2004 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import \u201cerlotinib tablets\u201d based on the information you provide.<\/p>\n
\nProprietary Name: On Request
\nActive Ingredient(s):\u00a0 erlotinib tablets
\nDosage Forms And Strengths: Tablets: 25 mg, 100 mg and 150 mg
\nCompany:
\nCurrent indications: non-small cell lung cancer (NSCLC)
\nMedicine Approved By: \u2013<\/strong>\u00a0European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a>
\n(see Drugs@FDA for complete indication)<\/p>\nAccess the best support services globally<\/h4>\n